Revenue Update on Codexis(NASDAQ:CDXS)

Codexis(NASDAQ:CDXS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $16.00M. Analysts estimated a revenue of $15.10M. Earnings per share were $0.12. Analysts had estimated an EPS of $0.03.

Codexis (CDXS) remained unchanged at the close of Wednesday session. Even as the volume increased to 91,683 ,the shares failed to make any impression and ended at 0 points or 0.00% at $4.14. The trading session commenced at $4.17 and the stock hit a high of $4.18 and touched $4.13 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $4.63 and the 52-week low is $2.93. The company has a market cap of $170 M and has approximately 4,11,81,099 outstanding shares.

Several Insider Transactions has been reported to the SEC. On Nov 12, 2015, James Lalonde (SVP, R&D) sold 9,441 shares at $3.52 per share price.Also, On Sep 15, 2015, Patrick Y Yang (director) purchased 10,000 shares at $3.47 per share price.On Sep 11, 2015, Bernard J Kelley (director) sold 5,200 shares at $3.45 per share price, according to the Form-4 filing with the securities and exchange commission.

Codexis Inc. is a developer of biocatalysts. The Company is engaged in the pharmaceutical and fine chemical industries. The Company’s CodeEvolver protein engineering technology platform is used in the evolution and optimization of biocatalysts to perform specific and desired chemical reactions at commercial scale. The pharmaceutical customers use its technology products and services in their manufacturing process development and production of drugs. The Company’s technologies enable scale-up and implementation of biocatalytic solutions for sustainable process development from research to manufacturing. The Company’s products include Codex screening panels and kits that enable customers to establish optimal reactions. The Company’s pharmaceutical products include enzymes pharmaceutical intermediates and Codex Biocatalyst Kits and Panels.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Codexis - Is it time to Sell?

Top Brokerage Firms are advising their investors on Codexis. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.